The British Journal of Psychiatry (2006) 189: 264-272. doi: 10.1192/bjp.bp.105.012799
© 2006 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Baldwin, D. S.
Right arrow Articles by Mæhlum, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baldwin, D. S.
Right arrow Articles by Mæhlum, E.

Escitalopram and paroxetine in the treatment of generalised anxiety disorder

Randomised, placebo-controlled, double-blind study*

David S. Baldwin, DM

Clinical Neuroscience Division, School of Medicine, University of Southampton, UK

Anna Karina Trap Huusom, MSc

H. Lundbeck A/S, Copenhagen, Denmark

Eli Mæhlum, MSc

H. Lundbeck A/S, Lysaker, Norway

Correspondence: David S. Baldwin, University Department of Mental Health, Royal South Hants Hospital, Graham Road, Southampton SO14 0YG, UK. Tel.: +44 (0) 2380 825 533, fax: +44 (0) 2380 234 243, email: dsb1{at}soton.ac.uk7

Declaration of interest The University of Southampton has received support from Lundbeck and GlaxoSmithKline. D.S.B. has received consultancy honoraria from Lundbeck and GlaxoSmithKline. A.K.T.H. and E.M. are employees of H. Lundbeck A/S, who sponsored this study.

* Some of the results in this manuscript were presented as a poster at the 17th Congress of the European College of Neuropsychopharmacology, Stockholm, Sweden, 9-13 October 2004

Background It is uncertain whether higher doses of selective serotonin reuptake inhibitors have greater efficacy in generalised anxiety disorder.

Aims To assess the efficacy of different doses of escitalopram in generalised anxiety disorder.

Method Randomised, double-blind, placebo-controlled, fixed-dose, parallel-group, 12-week study, with 681 patients: placebo (n=139); escitalopram, 5 mg/day, (n=134); 10 mg/day (n=136); 20 mg/day (n=133); paroxetine, 20 mg/day (n=139).

Results Mean change in the primary efficacy measure was greater with escitalopram 10 and 20 mg than with placebo; 10 mg was more efficacious than paroxetine. Paroxetine was superior to placebo on some secondary measures, at some time points. Compared with placebo, more patients withdrew because of adverse events with escitalopram 20 mg and paroxetine.

Conclusions Escitalopram was efficacious in generalised anxiety disorder, 20 was not significantly superior to 10 mg/day. Escitalopram 10 mg was more efficacious than paroxetine.


Related articles in BJP:

Highlights of this issue
Sukhwinder S. Shergill
BJP 2006 189: A9. [Full Text]  



This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
D. S Baldwin, E. H. Reines, C. Guiton, and E. Weiller
Escitalopram Therapy for Major Depression and Anxiety Disorders
Ann. Pharmacother., October 1, 2007; 41(10): 1583 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
C. Gale
Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder
Evid. Based Ment. Health, May 1, 2007; 10(2): 45 - 45.
[Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
D. J Stein
Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder
Evid. Based Ment. Health, February 1, 2007; 10(1): 23 - 23.
[Full Text] [PDF]